Sign in Subscribe

chemo

A collection of 72 issues

Mitochondrial Metabolism Drives 5-FU Resistance in Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH Mitochondrial Metabolism Drives 5-FU Resistance in Colorectal Cancer Preclinical research shows that 5-fluorouracil treatment promotes mitochondrial biogenesis and increased mitochondrial function in surviving colorectal cancer cells, and that targeting mitochondrial metabolism—particularly Complex I inhibition—can sensitize CRC cells to chemotherapy. (Nature Metabolism)

Non-Neutropenic Enterocolitis Risk Identified in Adjuvant CAPOX Therapy

Skip to content The CRC Digest ◇ RESEARCH Non-Neutropenic Enterocolitis Risk Identified in Adjuvant CAPOX Therapy A study examined the incidence and risk factors of non-neutropenic enterocolitis—a potentially serious side effect—in colorectal cancer patients receiving adjuvant capecitabine and oxaliplatin chemotherapy. (Clinical Colorectal Cancer) This content is informational only and

First-line immunotherapy outperforms chemotherapy in MSI-H/dMMR metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA First-line immunotherapy outperforms chemotherapy in MSI-H/dMMR metastatic colorectal cancer A meta-analysis of phase III trials confirms immune checkpoint inhibitors show superior progression-free and overall survival compared to standard chemotherapy as first-line treatment for patients with MSI-H or dMMR metastatic disease. (J

Circulating tumor DNA may identify which patients benefit from chemotherapy after liver metastasis surgery

Skip to content The CRC Digest ◆ TRIAL DATA Circulating tumor DNA may identify which patients benefit from chemotherapy after liver metastasis surgery The phase II GALAXY study (298 patients) found that ctDNA testing 2-10 weeks after surgery for colorectal liver metastases could help predict which patients are most likely to

Phase III trial finds no survival benefit from adding chemotherapy to surgery for peritoneal metastases

Skip to content The CRC Digest ◆ TRIAL DATA Phase III trial finds no survival benefit from adding chemotherapy to surgery for peritoneal metastases The CAIRO6 trial (351 patients) found that perioperative systemic therapy did not significantly improve overall survival compared to surgery alone in patients with resectable peritoneal-only metastases (44

Long-term outcomes reported for neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer

Skip to content The CRC Digest ▸ TREATMENT Long-term outcomes reported for neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer A multicentre study followed patients treated with bevacizumab combined with chemoradiation before surgery for locally advanced rectal cancer. (Clinical Colorectal Cancer) This content is informational only and does not constitute

BREAKWATER trial compares encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA BREAKWATER trial compares encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer This randomized study evaluated targeted therapy combinations specifically for patients with BRAF V600E mutations, a subtype associated with poorer outcomes. (Annals of Oncology) This

Clinical complete response in MSS/KRAS-mutant mCRC with immunotherapy combination

Skip to content The CRC Digest Clinical complete response in MSS/KRAS-mutant mCRC with immunotherapy combination Case report describes a 62-year-old woman with KRAS p.G12D, pMMR/MSS metastatic sigmoid colon cancer who achieved sustained regression with serplulimab, bevacizumab, and XELOX, with CEA declining from 3458.2 to 1812.84

Metronomic chemotherapy plus regorafenib tested in treatment-resistant metastatic colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Metronomic chemotherapy plus regorafenib tested in treatment-resistant metastatic colorectal cancer — ESMO Gastrointestinal Oncology The REPROGRAM-01 single-arm phase II trial tested regorafenib combined with metronomic capecitabine, cyclophosphamide, and aspirin in refractory metastatic colorectal cancer. This approach aims to improve outcomes in heavily pre-treated patients

Testing immunotherapy combination in MSS metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Testing immunotherapy combination in MSS metastatic colorectal cancer — Clinical Colorectal Cancer A Phase II study of pembrolizumab plus capecitabine and bevacizumab for microsatellite stable/mismatch repair-proficient metastatic colorectal cancer. Most colorectal cancers are MSS/pMMR and don't respond well to